Effects of chaducanumab‐mediated plaque removal on amyloid‐tau synergy
Lindsay A Welikovitch, Anastasie Mate de Gerando, Anita Khasnavis, Harshil Bhavsar, Jonah C Meltzer, Luc Buee, Thierry Bussière, Bradley T. T Hyman · 2025
Read Effects of chaducanumab‐mediated plaque removal on amyloid‐tau synergy by Lindsay A Welikovitch, Anastasie Mate de Gerando, Anita Khasnavis, Harshil Bhavsar, Jonah C Meltzer, Luc Buee, Thierry Bussière, Bradley T. T Hyman (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11710244.txt.
Description
Lindsay Welikovitch and co-authors test in 2025 whether clearing amyloid plaques from the brain also slows the tau tangles of Alzheimer disease. Drug antibodies clear plaques well in patients, but most animal tests modeled amyloid alone. Their mice carried both plaque and tangle traits, which mirrors patients more closely.
After three months of weekly antibody doses, treated mice had far fewer plaques in two brain regions. Yet tangle counts did not budge in any region, even though amyloid is known to speed tangle growth in this strain. The result suggests plaque clearing alone may not stop the tau side of the disease once it is under way.
Catalog record
| CREATOR | Lindsay A Welikovitch, Anastasie Mate de Gerando, Anita Khasnavis, Harshil Bhavsar, Jonah C Meltzer, Luc Buee, Thierry Bussière, Bradley T. T Hyman |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |